TY  - JOUR
AU  - Guerra Veloz, María Fernanda
AU  - Argüelles-Arias, Federico
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belén
AU  - Benítez Roldan, Antonio
AU  - Perea Amarillo, Raúl
AU  - Merino Bohórquez, Vicente
AU  - Calleja, Miguel Angel
AU  - Caunedo Álvarez, Ángel
AU  - Vilches Arenas, Ángel
PY  - 2018
DO  - 10.3748/wjg.v24.i46.5288
UR  - http://hdl.handle.net/10668/13353
T2  - World journal of gastroenterology
AB  - Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish...
LA  - en
KW  - Biosimilar agent
KW  - CT-P13
KW  - Crohn’s disease
KW  - Efficacy
KW  - Inflammatory bowel disease
KW  - Infliximab original
KW  - Ulcerative colitis
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Biosimilar Pharmaceuticals
KW  - Drug Substitution
KW  - Female
KW  - Follow-Up Studies
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Treatment Outcome
TI  - Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
TY  - research article
VL  - 24
ER  -